Department of Neurology, Fujian Provincial Geriatric Hospital, Fuzhou, China.
Stroke Research Center, Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Neurol Sci. 2022 Oct;43(10):5993-6002. doi: 10.1007/s10072-022-06233-2. Epub 2022 Jun 29.
Whether intravenous thrombolysis provides additional benefits before direct endovascular treatment (dEVT) in acute ischemic stroke remains unclear. We aimed to compare the functional and safety outcomes of dEVT to endovascular treatment with bridging using intravenous thrombolysis (BT) in acute ischemic stroke.
This meta-analysis included currently available eligible randomized clinical trials (RCTs) by searching in the PubMed, EMBASE, Cochrane Central Register, and the International Stroke Conference and European Stroke Organisation Conference posted abstracts.
The six included RCTs yielded 2334 participants (mean age, 69.8 years [SD, 11.4]; women, 44.3%; 1164 in dEVT group and 1170 in BT group). We found not significantly different 90-day functional outcomes of modified Rankin scale (mRS 0 - 2, odds ratio [OR] 0.93, 95%CI 0.79 - 1.09; mRS 0 - 1, OR 0.99, 95%CI 0.82 - 1.18), mortality (OR 1.08, 95%CI 0.86 - 1.35), and symptomatic intracranial hemorrhage (OR 0.72, 95%CI 0.49 - 1.07) for patients in dEVT and BT group. Patients treated with dEVT were less likely to experience successful recanalization (OR 0.72, 95%CI 0.57 - 0.92, p = 0.009) and any intracranial hemorrhage (OR 0.81, 95%CI 0.68 - 0.97, p = 0.02). There were no significant differences regarding procedural complications between the two groups.
This meta-analysis showed no significant differences in 90-day functional outcomes or mortality between dEVT and BT, but a lower possibility of successful recanalization and intracranial hemorrhage for dEVT.
在急性缺血性脑卒中患者中,直接血管内治疗(dEVT)前静脉溶栓是否能带来额外获益仍不明确。我们旨在比较急性缺血性脑卒中患者接受 dEVT 与血管内治疗联合桥接静脉溶栓(BT)的功能结局和安全性。
本荟萃分析通过检索 PubMed、EMBASE、Cochrane 中心注册库以及国际卒中会议和欧洲卒中组织会议的已发表摘要,纳入了目前可用的合格随机临床试验(RCT)。
纳入的 6 项 RCT 共纳入 2334 名患者(平均年龄 69.8 岁[标准差 11.4];女性占 44.3%;dEVT 组 1164 例,BT 组 1170 例)。我们发现 dEVT 组和 BT 组 90 天改良 Rankin 量表(mRS)0-2 评分(比值比 [OR] 0.93,95%置信区间 [CI] 0.79-1.09;mRS 0-1,OR 0.99,95%CI 0.82-1.18)、死亡率(OR 1.08,95%CI 0.86-1.35)和症状性颅内出血(OR 0.72,95%CI 0.49-1.07)无显著差异。接受 dEVT 治疗的患者更有可能实现成功再通(OR 0.72,95%CI 0.57-0.92,p=0.009)和任何颅内出血(OR 0.81,95%CI 0.68-0.97,p=0.02)的风险降低。两组间的操作并发症无显著差异。
本荟萃分析表明,dEVT 与 BT 治疗在 90 天功能结局或死亡率方面无显著差异,但 dEVT 再通和颅内出血的可能性较低。